Cancer immunotherapy attempts to harness the immune system by breaking tolerance and generating a robust anticancer response. We have recently demonstrated a synergistic enhancement in tumor clearance following therapeutic, dual PD-1 and LAG-3 blockade. Here, we discuss the implications of these findings in the context of future combinatorial immunotherapeutic approaches.